Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate

Paolo Vercellini; Giuliana Pietropaolo; Olga De Giorgi; Roberta Pasin; Annalisa Chiodini; Pier Giorgio Crosignani

doi:10.1016/j.fertnstert.2005.03.083

Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate

Paolo Vercellini, Giuliana Pietropaolo, Olga De Giorgi, Roberta Pasin, Annalisa Chiodini, Pier Giorgio Crosignani

Fertility and sterility · 2005 · vol. 84(5) , pp. 1375–1387 · doi:10.1016/j.fertnstert.2005.03.083 · PMID:16275232 · W2062896185

article OA: closed CC0 ⤵ 167 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study compared the efficacy of an estrogen–progestogen combination versus low-dose norethindrone acetate in treating symptomatic rectovaginal endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisbowel_endometriosis

MeSH descriptors

Endometriosis Estrogen Replacement Therapy Estrogens Norethindrone Progestins Rectal Diseases Vaginal Diseases Adolescent Adult Confidence Intervals Drug Therapy, Combination Endometriosis Endometriosis Estrogen Replacement Therapy Estrogens Female Humans Middle Aged Norethindrone Norethindrone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate? via openalex
Comparison of Cyproterone Acetate and Danazol in the Treatment of Pelvic Pain Associated With Endometriosis via openalex
Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen via openalex
Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis via openalex
Dosage aspects of danazol therapy in endometriosis. via openalex
Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
Effect of norethindrone acetate in the treatment of symptomatic endometriosis. via openalex
Endometriosis and pelvic pain via openalex
Endometriosis: Complications of CO2-laser endoscopic excision of deep endometriosis via openalex
Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum via openalex
Long-term follow-up after conservative surgery for rectovaginal endometriosis via openalex
Long-term treatment of symptomatic endometriosis with norethindrone acetate via openalex
Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis via openalex
Pain, quality of life and complications following the radical resection of rectovaginal endometriosis via openalex
Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome via openalex
Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex
Progestogens for endometriosis: forward to the past via openalex
Prolonged GnRH Agonist and Add-Back Therapy for Symptomatic Endometriosis via openalex
Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 via openalex
Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy via openalex
Treatment of endometriosis with cyproterone acetate. Preliminary report. via openalex
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis via openalex
W6820046625 via openalex
W2064107649 via openalex
W1981675177 via openalex
W2401134385 via openalex
W143921209 via openalex
W2477008945 via openalex
W6601145584 via openalex
W6602916246 via openalex
W6607311167 via openalex
W6633460794 via openalex
W2024158781 via openalex

Cited by (50)

Source provenance

europepmc: last seen: 2026-06-04T01:30:01.192114+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-05-13T22:15:29.922408+00:00

License: CC0 · commercial use OK

[1] Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate? via openalex

[2] Comparison of Cyproterone Acetate and Danazol in the Treatment of Pelvic Pain Associated With Endometriosis via openalex

[3] Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen via openalex

[4] Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis via openalex

[5] Dosage aspects of danazol therapy in endometriosis. via openalex

[6] Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex

[7] Effect of norethindrone acetate in the treatment of symptomatic endometriosis. via openalex

[8] Endometriosis and pelvic pain via openalex

[9] Endometriosis: Complications of CO2-laser endoscopic excision of deep endometriosis via openalex

[10] Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum via openalex

[11] Long-term follow-up after conservative surgery for rectovaginal endometriosis via openalex

[12] Long-term treatment of symptomatic endometriosis with norethindrone acetate via openalex

[13] Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis via openalex

[14] Pain, quality of life and complications following the radical resection of rectovaginal endometriosis via openalex

[15] Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome via openalex

[16] Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex

[17] Progestogens for endometriosis: forward to the past via openalex

[18] Prolonged GnRH Agonist and Add-Back Therapy for Symptomatic Endometriosis via openalex

[19] Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 via openalex

[20] Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy via openalex

[21] Treatment of endometriosis with cyproterone acetate. Preliminary report. via openalex

[22] Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis via openalex

[23] W6820046625 via openalex

[24] W2064107649 via openalex

[25] W1981675177 via openalex

[26] W2401134385 via openalex

[27] W143921209 via openalex

[28] W2477008945 via openalex

[29] W6601145584 via openalex

[30] W6602916246 via openalex

[31] W6607311167 via openalex

[32] W6633460794 via openalex

[33] W2024158781 via openalex